AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02207491
Drug: Timolol maleate Ophthalmic Solution 0.5% BID
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop BID, AM/PM, OU
Trial: NCT00277589
Drug: Iodide
RxNorm normalized name: Iodide
DrugBank: Iodide (DB12754)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet 30 minutes before breakfast
Trial: NCT00462878
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic
Trial: NCT00462878
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT00462878
Drug: Teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT00981877
Drug: GB (Florestor)
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. Boulardii preparation of 1 gram twice daily for 5 days
Trial: NCT00981877
Drug: GRALB
RxNorm normalized name: Gralise
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mixed probiotic preparation 1 gram twice daily for 5 days.
Trial: NCT00061360
Drug: ATG+Rapamune+cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG+Rapamune+cyclosporine
Trial: NCT00981877
Drug: GC (placebo)
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 gram twice daily for 5 days.
Trial: NCT02233803
Drug: Salbutamol 100 mcg pMDI
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
Trial: NCT04160026
Drug: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine
DrugBank: Piperaquine (DB13941)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
Trial: NCT00061360
Drug: ATG+cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG+cyclosporine
Trial: NCT04160026
Drug: Monthly intermittent preventive treatment with sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
Trial: NCT04160026
Drug: Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine with targeted information transfer
DrugBank: Piperaquine (DB13941)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Feasibility study to assess adherence to guidelines among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
Trial: NCT01374568
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sitagliptin 100mg daily
Trial: NCT00484029
Drug: Nasal Carbon Dioxide
RxNorm normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal Carbon Dioxide
Trial: NCT04224857
Drug: AMT-101
RxNorm normalized name: AMT-101
DrugBank: AMT-101 (DB18555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or daily dosing at doses A, B, C, D, E, F
Trial: NCT02922673
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003124
Drug: flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003124
Drug: leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01661764
Drug: Oleic Acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00666692
Drug: M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
Trial: NCT01383655
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: i.v. magnesium 40mg/kg in 20 min
Trial: NCT00214552
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02601586
Drug: PR Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PR Oxycodone
Trial: NCT02601586
Drug: Oxycodone Placebo
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo of PR Oxycodone
Trial: NCT00805805
Drug: Tetrathiomolybdate
RxNorm normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
Trial: NCT04507672
Drug: Fluid resuscitation
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use the choice of crystalloid for resuscitation during the first 72 hours after enrollment
Trial: NCT03752970
Drug: Spesolimab
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).
Trial: NCT00043433
Drug: intravenous T900607-sodium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03949153
Drug: Ipilimumab Injection
RxNorm normalized name: ipilimumab Injection
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In situ injection with ipilimumab at D2.
Trial: NCT00091559
Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00353041
Drug: lidocaine topical
RxNorm normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01425619
Drug: Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
Trial: NCT00293501
Drug: tinzaparin sodium
RxNorm normalized name: Tinzaparin Sodium
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03478904
Drug: Enzalutamide Liquid
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide liquid formulation given orally (160mg)
Trial: NCT03478904
Drug: Enzalutamide Capsule
RxNorm normalized name: Enzalutamide Capsules
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide gel capsule (4X 40mg)
Trial: NCT00680446
Drug: Immunoglobulin G (Ig NextGen 16%)
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
Trial: NCT03800953
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
Trial: NCT01565278
Drug: Soybean oil (Standard treatment)
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
Trial: NCT01565278
Drug: Soybean oil + Fish oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
Trial: NCT03377478
Drug: Epclusa
RxNorm normalized name: Epclusa
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
Trial: NCT04385550
Drug: Anlotinib hydrochloride capsule
RxNorm normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Trial: NCT04385550
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.
Trial: NCT04385550
Drug: Docetaxel injection
RxNorm normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.
Trial: NCT04343222
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drops to lubricate the eye and maintain moisture
Trial: NCT03225846
Drug: WVE-120102
RxNorm normalized name: WVE 003
DrugBank: WVE-003 (DB17870)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WVE-120102 is a stereopure antisense oligonucleotide (ASO)
Trial: NCT01747551
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01747551
Drug: Ziv-aflibercept
RxNorm normalized name: Ziv-Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03759782
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.
Trial: NCT03759782
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir as per standard of care
Trial: NCT01883102
Drug: Capsaicin 0.1%
RxNorm normalized name: CAPSAICIN 0.1% CREAM
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
Trial: NCT00126698
Drug: trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00126698
Drug: ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02720120
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
Trial: NCT00002775
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002775
Drug: estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01869023
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
Trial: NCT01869023
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
Trial: NCT04098562
Drug: LL37
RxNorm normalized name: Cathelicidin LL-37
DrugBank: LL-37 (DB16532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream
Trial: NCT03991208
Drug: Malarone
RxNorm normalized name: Malarone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Malarone
Trial: NCT03796377
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg rivaroxaban.
Trial: NCT02839889
Drug: Naloxegol
RxNorm normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
Trial: NCT04353505
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial delivery of Dexamethasone in the internal maxillary artery, once.
Trial: NCT01865747
Drug: Cabozantinib tablets
RxNorm normalized name: cabozantinib Oral Tablet
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01865747
Drug: Everolimus (Afinitor) tablets
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00542542
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-2.5 mg/kg IV over 1-4 hours during surgery.
Trial: NCT00542542
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine given by injection into the paravertebral space along the spinal canal.
Trial: NCT00542542
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.08 mg/kg IV over 1-4 hours during the surgery.
Trial: NCT04554485
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults
Trial: NCT00245596
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01730014
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
Trial: NCT01730014
Drug: sodium chloride 0.9% w/v
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
Trial: NCT00996580
Drug: DR-103
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE.
Trial: NCT00336518
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00336518
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00064025
Drug: Medroxyprogesterone
RxNorm normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT01173640
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg oral dose
Trial: NCT02548286
Drug: Candesartan 8mg
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, 1day or 22day
Trial: NCT02548286
Drug: Amlodipine 5mg
RxNorm normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO, 1day or 22day
Trial: NCT00453167
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
Trial: NCT00453167
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
Trial: NCT00547014
Drug: 52364 3 mg
RxNorm normalized name: lusutrombopag 3 MG
DrugBank: Lusutrombopag (DB13125)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg capsule single dose administered orally as a single dose
Trial: NCT00547014
Drug: 52364 10 mg
RxNorm normalized name: dronabinol 10 MG
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: 52364 30 mg capsule as a single dose
Trial: NCT00547014
Drug: 52364 30 mg
RxNorm normalized name: pasireotide 30 MG
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: 52364 30 mg capsule administered as a single dose
Trial: NCT00547014
Drug: 52364 1 mg
RxNorm normalized name: haloperidol 1 MG
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
Trial: NCT05083390
Drug: norUrsodeoxycholic acid
RxNorm normalized name: NorUrsodeoxycholic Acid
DrugBank: norUrsodeoxycholic acid (DB16260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg norUrsodeoxycholic acid or placebo film-coated tablets; 3 tablets/day
Trial: NCT01718808
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
Trial: NCT02097953
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02097953
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02880787
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
Trial: NCT03668639
Drug: Akynzeo
RxNorm normalized name: Akynzeo
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly administration of akynzeo for five weeks.
Trial: NCT03668639
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
Trial: NCT02639039
Drug: Cortisone Injection
RxNorm normalized name: hydrocortisone Injection
DrugBank: Cortisone acetate (DB01380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
Trial: NCT00450515
Drug: vinflunine
RxNorm normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696163
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
Trial: NCT04557267
Drug: low-dose
RxNorm normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage 1
Trial: NCT04557267
Drug: Middle-dose
RxNorm normalized name: wheat middlings extract
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage 2